ANTI-OBESITY DRUG MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Market Segmentation

• Drug Type Insights (Revenue, USD Bn, 2023 - 2035)

  • Prescription Drugs
  • Over-the-Counter (OTC) Drugs

•  Drug Class Insights (Revenue, USD Bn, 2023 - 2035)

  • GLP-1 Receptor Agonists
    • Semaglutide
    • Liraglutide
    • Tirzepatide
  • MC4R (Melanocortin-4 Receptor) Agonists
    • Setmelanotide
  • Lipase Inhibitors
    • Orlistat
  • Noradrenergic & Serotonergic Drugs
    • Phentermine
    • Diethylpropion
    • Phendimetrazine
  • Combination Therapies
    • Phentermine/Topiramate
    • Naltrexone/Bupropion
    • Others
  • Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors
    • Empagliflozin
    • Canagliflozin
  • Bile Acid Sequestrants
    • Colesevelam
  • Amylin Analogs
    • Pramlintide
  • Others (Late Phase Drugs, etc.)

•  Route of Administration Insights (Revenue, USD Bn, 2023 - 2035)

  • Oral
  • Parenteral
  • Others (Transdermal)

•  Type Insights (Revenue, USD Bn, 2023 - 2035)

  • Brand
  • Generic

•  Gender Insights (Revenue, USD Bn, 2023 - 2035)

  • Male
  • Female

•  Age Group Insights (Revenue, USD Bn, 2023 - 2035)

  • Adult
  • Geriatric
  • Pediatric

•  Distribution Channel Insights (Revenue, USD Bn, 2023 - 2035)

  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies

• Regional Insights (Revenue, USD Bn, 2023 - 2035)

  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa